Battelle Memorial Institute

Battelle Memorial Institute's Pacific Northwest National Laboratory Division, doing business as Pacific NW National, operates as a federal research grant and contract recipient providing mass spectrometry-based analytical chemistry, structural biology, proteomics, lipidomics, metabolomics, and biomedical research services to the National Institutes of Health, the Department of Energy, and other federal agencies. PNNL is a tax-exempt nonprofit and a division of Battelle Memorial Institute headquartered in Columbus, Ohio; the laboratory operates as a prime grant recipient (61% of recent awards) and subcontractor (39% of recent awards), with no SBA set-aside posture.

PNNL's capability portfolio centers on multimodal omics analysis platforms and advanced analytical instrumentation. Recent prime grant work includes a $2.843 million National Institute of General Medical Sciences award to develop a next-generation ultra-high resolution ion mobility spectrometer platform for metabolomics research; a $1.92 million National Institute of Diabetes and Digestive and Kidney Diseases award to identify prohormone processing products as blood-based mechanistic markers of islet cell dysfunction across Type 1 Diabetes progression; a $1.688 million NIGMS award to develop a multimodal measurement platform for unambiguous lipid identification using high-resolution ion mobility-mass spectrometry and ultraviolet photodissociation; and a $492,167 NIGMS award to develop a high-throughput multiomic platform for simultaneous single-cell profiling of proteins, transcripts, and metabolites. PNNL also operates the Proteome Characterization Center as part of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), delivering comprehensive proteogenomic characterization of human cancers with extended acetylome, ubiquitinome, metabolome, and lipidome analysis; this cooperative agreement spans five years from June 2022 through May 2027.

Customer concentration is heavily weighted to the National Institutes of Health ecosystem. The top five NIH funding entities account for 113 of the 264 total awards in the portfolio: the NIH broadly (40 awards), the Office of the Director (22 awards), the National Institute of Diabetes and Digestive and Kidney Diseases (18 awards), the National Institute of Environmental Health Sciences (17 awards), and the National Institute on Aging (16 awards). By dollar magnitude, the Department of Energy Office of Science dominates with 9 awards carrying the combined potential value of $35.17 billion, representing 100% of PNNL's combined potential value in the source data—a signal that reflects PNNL's long-standing role as a DOE national laboratory. This concentration represents a structural advantage: PNNL's grants and contracts are anchored to stable, multi-year federal research funding rather than competitive procurement.

PNNL maintains active subcontract relationships with prime defense and engineering contractors. Named subcontracting relationships include work under Consolidated Nuclear Security LLC on management and operating contracts for the Y-12 National Security Complex, Pantex Plant, and Savannah River Tritium Operations; work under Assured Information Security, Inc. on the Archangel Azrael and TENSHU defense engineering programs and the 16th Air Force VALIANT program (multiple sub-awards from 2024–2025); work under Fluor Marine Propulsion LLC on Naval Nuclear Laboratory operations and neutron detector testing; and work under The Charles Stark Draper Laboratory on medical countermeasure evaluation platforms with vascular-immune and small intestine-immune organ-on-chip models.

PNNL's grant subrecipient footprint is extensive and deeply integrated with the NIH research ecosystem. The laboratory acts as a subrecipient on 56 federal grant sub-awards to university lead institutions, primarily delivering mass spectrometry-based omics analyses. Representative recent subaward work includes multiomic analysis for the University of North Carolina on urban heat stress mapping using satellite data and machine learning; spatial multi-omics profiling for University of Chicago on Type 1 Diabetes pathogenesis mechanisms; proteomics and metabolomics analysis for University of Florida on novel neoantigens in Type 1 Diabetes; LC-MS proteomics for UCLA on pulmonary fibrosis cell-cell and cell-matrix interactions as part of the LungMAP Phase 3 U01 Research Center; and ultrasensitive proteome profiling for University of Washington on the Pacific Northwest component of the US Integrated Ocean Observing System (NANOOS). PNNL also serves as a subaward performer under Oregon State University on multiple tranches of the Center for the Science, Technology, and Emerging Health Risks of Polycyclic Aromatic Hydrocarbons project (eight sub-awards from 2024–2026).

Activity has grown substantially year over year, from 10 awards in 2022 to 42 in 2024, with 25 awards in 2026 (through August). The recompete cliff is material: 16 awards with ultimate completion dates within the next twenty-four months carry a combined potential value of $35.17 billion, concentrated almost entirely in DOE Office of Science cooperative agreements and facility operating contracts. PNNL's SCI-reported federal service contract activity is minimal, covering only 8 records as a named subcontractor (zero prime SCI contracts), with FTE trajectories ranging from 44.8 to 70.1 FTEs across fiscal years 2022–2025—a reflection that PNNL's federal engagement is overwhelmingly grant-based rather than service-contract-based. The laboratory operates as a feeder subcontractor to defense and national security primes (Consolidated Nuclear Security, Assured Information Security, Fluor Marine Propulsion, Draper Laboratory) and as a specialized omics subrecipient to NIH-funded university research consortia, rather than as an independent prime in the commercial federal market.